Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.
2.

The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.

Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH; Investigators.

Cephalalgia. 2002 Sep;22(7):523-32.

PMID:
12230594
3.

Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study.

Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M.

Cephalalgia. 1996 Oct;16(6):436-40.

PMID:
8902254
4.
5.
6.
7.

Divalproex sodium in migraine prophylaxis: a dose-controlled study.

Klapper J.

Cephalalgia. 1997 Apr;17(2):103-8. Erratum in: Cephalalgia 1997 Nov;17(7):798.

PMID:
9137847
8.

Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.

Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW.

Headache. 2007 Jul-Aug;47(7):1037-49.

PMID:
17635595
9.

Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM; BOTOX North American Episodic Migraine Study Group.

Headache. 2007 Apr;47(4):486-99.

PMID:
17445098
10.

Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.

Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA.

Headache. 2006 Jan;46(1):115-24.

PMID:
16412159
11.

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group.

Headache. 2005 Apr;45(4):293-307.

PMID:
15836565
12.

Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR.

Headache. 2002 Jun;42(6):470-82.

PMID:
12167135
13.

Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone.

Cleland PG, Barnes D, Elrington GM, Loizou LA, Rawes GD.

Eur Neurol. 1997;38(1):31-8.

PMID:
9252796
14.
16.

Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial.

Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ.

Headache. 2003 Jun;43(6):601-10.

PMID:
12786918
17.

Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.

Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, Lines CR, Reines SA; Protocol 125 study group.

Headache. 2004 Jun;44(6):581-6.

PMID:
15186302
18.

Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A.

Cephalalgia. 2004 Oct;24(10):838-43.

PMID:
15377314
19.

Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.

Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG; Tonabersat TON-01-05 Study Group.

Cephalalgia. 2009 Jul;29(7):742-50. doi: 10.1111/j.1468-2982.2008.01804.x. Epub 2009 Feb 13.

PMID:
19222510
Items per page

Supplemental Content

Write to the Help Desk